NYSE:TEVAPharmaceuticals
Will Teva’s New TD Data on Young Adults Shift Its Neuroscience-Focused Investment Narrative (TEVA)?
Earlier in May 2026, Teva Pharmaceutical Industries presented new real-world data from its three-year IMPACT-TD Registry at the American Psychiatric Association meeting, revealing that young adults with mood disorders and tardive dyskinesia often face delayed recognition and low formal diagnosis rates despite substantial daily life impact.
The findings underline a pronounced diagnostic gap in tardive dyskinesia for patients under 40, especially those aged 18–29, who report high psychological...